QUANTUM GENOMICS
Société anonyme au capital de 4.483.714,74 euros
Siège social : Tour Maine Montparnasse - 33, avenue du Maine
75015 Paris
487 996 647 R.C.S. Paris

RENSEIGNEMENTS RELATIFS A UNE CANDIDATURE AUX FONCTIONS D'ADMINISTRATEUR

PRESENTEE A L'ASSEMBLEE GENERALE DU 14 JUIN 2018 (8EME RESOLUTION)

NOM ET PRENOM USUEL : KRESS Jean-Paul

DOMICILE : 50 Gay Street, Boston, MA 02116, Etats-Unis

DATE ET LIEU DE NAISSANCE : 1er août 1965 à Strasbourg (69)

REFERENCES PROFESSIONNELLES ET ACTIVITES EXERCEES DANS D'AUTRES SOCIETES, AU COURS DES CINQ DERNIERES ANNEES :

Jean-Paul KRESS, français vivant à Boston, est médecin avec un cursus complémentaire en Biochimie et pharmacologie réalisé à l'Ecole Normale Supérieure de Paris.

Il a 25 ans d'expérience dans le domaine biopharmaceutique en France et à l'international avec une bonne connaissance du domaine cardiovasculaire mais aussi de lancement de produits et de management global acquis au sein de compagnies comme Smithkline, Abbott, Lilly, Gilead, Sanofi Pasteur, Sanofi Genzyme et Biogen.

Il dirige actuellement Syntimmune société basée à Boston développant de nouveaux produits pour traiter les maladies auto-immunes.

Jean-Paul Kress a été membre du Board de Sarepta Therapeutics (NASDAQ SRPT).

Jean-Paul Kress apportera au Conseil d'Administration ses compétences mais aussi sa grande connaissance du marché Nord-Américain.

EMPLOIS OU FONCTIONS EXERCEES DANS LA SOCIETE :

Administrateur

Jean-Paul KRESS, M.D.
50 Gray Street
Boston, MA 02116, USA

Monsieur Lionel SEGARD
Founder and Chairman
Quantum Genomics

Boston, le 7 mai 2018

Cher Monsieur,

Je vous confirme par la presente mon souhait de devenir administrateur de Quantum Genomics, et par la meme de contribuer a son developpement dans la lute contre les maladies cardio-vasculaires.

Mon experience en Europe et aux Etats-Unis dans des postes de Senior Management et d'administrateur au sein de companies biopharmaceutiques de premier plan, ainsi que ma formation medicale et scientifique au sein d'etablissements francais d'excellence (Necker, ENS Ulm) me semblent importants pour ce poste d'administrateur.

Enfin, etant actuellement President et CEO d'une Biotech a Boston, je suis a meme de comprendre la problematique d'une jeune societe et de son implantation aux Etats-Unis.

Je reste a votre disposition pour en discuter.

Veuiller croire, Cher Monsieur, en l'assurance de mes sentiments les meilleurs.

JEAN-PAUL KRESS, MD

Boston, Massachusetts 02116, USA • jeanpaul.kress@gmail.com • (617) 312-5003

GLOBAL LIFE SCIENCES EXECUTIVE

Twenty-five years of global experience in biopharma with a reputation for vision, leadership, and effectiveness; proven track record of launching and strategically repositioning specialty, rare disease, and vaccine businesses, driving the operations that deliver results and recruiting and developing the talent to succeed. Passion for building and leading high-performing teams. Board experienced. A true global and multicultural executive, have lived in the US, Denmark and in France, driving business growth in most geographies. Strong scientific and medical academic background, combined business experience in many therapeutic areas have shaped ability to quickly understand and leverage new opportunities. Career highlights include:

- As a former President and CEO of SANOFI PASTEUR MSD, a leading European vaccine company, led a fully integrated $1billion (B) P&L with 1,300 FTEs from 2011 to 2015.
- As SVP and Executive Leadership Team member OF SANOFI GENZYME, headed the North America Business Units (>$2B revenue) and was instrumental in launching Dupixent, the first biologic approved in Atopic Dermatitis, in collaboration with Regeneron, and bringing about the company's transformation in the US.
- International experience at GILEAD leading the Antiviral US Business Unit and then the French affiliate. Increased Affiliate Revenue by 10% CAGR 08-10,Launched ATRIPLA, the first and only once-daily single tablet triple combination regimen for the treatment of HIV and increased US Antiviral sales by 49%.
- As General Manager, ABBOTT LABORATORIES A/S, in Copenhagen, Denmark, increased affiliate sales by 30% and industry ranking position from number 23 in 2003 to number 13 in 2005; successfully launched HUMIRA.
- On Board of SAREPTA THERAPEUTICS when the company successfully went through their first FDA approval and US launch. Also Board member of the prestigious ECOLE NORMALE SUPÉRIEURE ALUMNI ASSOCIATION.

EXPERIENCE

SYNTIMMUNE, Boston, MA, USA — Since Jan 2018

President and Chief Executive Officer

BIOGEN, Cambridge, MA, USA — 2017

Executive Vice President, President International & Head of Global Therapeutic Operation

Reporting to CEO, managed Biogen $3B International P&L and provide operational and strategic leadership to define and successfully execute Biogen's commercialization strategy globally. Member, Biogen Executive Committee. Drove revenue and earnings growth across Specialty Medicines and Rare Disease across Europe and Canada, APAC and LATAM. Global leadership over the Specialty Medicines and Rare Disease Asset Teams, Global Marketing and led the Phase 3 program and life cycle management of all in line and pipeline assets, Global Market Access, Sales and Marketing Effectiveness.

SANOFI GENZYME, Cambridge, MA, USA — 2015 – 2017

Senior Vice President, Head of North America

Led Sanofi Genzyme Specialty Care North America Operations and P&L. In charge of four US Business Units: Multiple Sclerosis, Oncology, Immunology (Rheumatology and Dermatology/Asthma), and Canada. 2016 sales in excess of €2B Euros. Managed a staff of 850 solid line, and business partners dotted line. Led the US Joint Commercial Committee with Regeneron. Member Sanofi Genzyme Executive Leadership Team and Sanofi US Country Council.

- Launched anti IL-4 IL-13 Dupilumab, first and only biologic in Atopic Dermatitis. Hired best-in-class Dermatology experienced commercial, medical affairs, and national accounts teams to launch multi-billion US$ blockbuster potential, key for Sanofi's future.
- Led all aspects of launch preparation for anti IL-6 Sarilumab in RA. Hired best in class Rheumatology experienced commercial, medical affairs and national accounts teams. Leverage strong Sarilumab product profile to establish Sanofi Genzyme as a new key player in a US$10B RA market ultra-dominated by TNF-alpha products.

- Continued strong growth (>50% in 2016) of the €1.2B Multiple Sclerosis Franchise with oral agent Aubagio and transformative infusion agent Lemtrada, in a very competitive and large MS US market. Leveraged best-in-class Sanofi Genzyme MS launch strategies, tactics and know-how for the new immunology products.

(SANOFI GENZYME, **SVP, Head of North America**, continued)

- Grew single-digit €500 million (M) Oncology sales (Jevtana in Prostate Cancer) and Transplant Franchise (Thymoglobulin and Mozobil), leveraging the strong Sanofi legacy and bridging with renewed Corporate ambitions in oncology (strengthened R&D pipeline, active and potentially transformational BD moves).
- Established the new Sanofi Genzyme organization in North America as part of Sanofi CEO's Forward Project.

SANOFI PASTEUR MSD, Lyon and Paris, France 2011 – 2015

President and CEO

Responsible for all aspects of the business of leading European vaccine company (a joint venture by Merck and Sanofi). Responsibilities included sales and marketing, access to market, supply chain support functions, medical affairs, development, regulatory/PV/quality. 2014 revenue €860M. Led a team of 1100 professionals across 19 countries.

- Embarked on a series of changes to reshape the organization to better meet the challenges of the rapidly changing vaccine industry and to drive the launches of a number of innovative new products, like Hexyion (hexavalent pediatric) and Zostavax (shingles).
- Mobilized the organization to focus on the most critical priorities, resulting in a turnaround of the business.
- Achieved above market revenue growth in a challenging EU environment and despite supply constrains. Achieved strong Operating Income improvement. Established SPMSD as THE European vaccine company, strongly advocated for socio-economic value of vaccination, active involvement in development of health policy across EU.

GILEAD SCIENCES, Paris, France | Foster City, CA, USA 2006 – 2011

Vice President and General Manager, GILEAD France, Paris, France *(2008 – 2011)*

Responsible for all aspects of the Business for Gilead in France, leading the number one affiliate after the USA, with 2010 revenue of €400M. Managed a staff of 120 and reports to the SVP, International Commercial Operations.

- Increased Affiliate Revenue by 10% CAGR (2008 – 2010).
- Launched ATRIPLA, the first and only once-daily single tablet triple combination regimen for the treatment of HIV, after complex Pricing and Reimbursement negotiation.
- Rebuilt Senior Leadership team and reorganized operations into Business Units.

Vice President, US Sales & Marketing, Antiviral Business Unit, Foster City, CA, USA *(2006 – 2008)*

Responsible for all aspects of HIV and Hepatitis Sales & Marketing for the USA, with 2008 revenue in excess of $2.5 B and expense budget over $100M. Managed a staff of 180 Sales professionals and 24 Marketing executives, including five direct reports at Senior Director level. Reported to the Senior Vice President, North America Commercial.

- Increased US Antiviral sales by 49% from $1.4B in 2006 to $2.7B in 2008.
- Launched ATRIPLA in July 2006, the first and only once-daily single tablet triple combination regimen for the treatment of HIV, achieving the number one antiretroviral launch in the history of new HIV medications in terms of market share gain and $ revenue ($900M in 2007).
- Increased Gilead's antiviral market leadership to 65% HIV patient share and 80% HIV new patient share.
- Launched Viread for Hepatitis B in August 2008.
- Built Senior Leadership team and Field Leadership team, with focus on Operational Excellence.

ABBOTT LABORATORIES, Copenhagen, Denmark | Paris, France | Chicago, IL, USA 1997 – 2006

General Manager, Abbott Laboratories A/S, Copenhagen, Denmark *(2002 – 2006)*

Responsible for all aspects (commercial, medical, regulatory and financial) of Abbott Laboratories' business in Denmark. Full responsibility for sales ($35M) and P&L. Managed a staff of 70 employees, including six direct reports. Reported to the Regional Director of Northern Europe.

- Increased affiliate sales by 30% in 2004.

- Increased Abbott Denmark industry ranking position from number 23 in 2003 to number 13 in 2005.
- Successfully launched HUMIRA®, a new sub-Q anti-TNF alpha for the treatment of rheumatoid arthritis, achieving market leader position within 12 months.
- Achieved affiliate certification for Class A business excellence process.

Director, Cardiovascular Business Unit, International Marketing & Business Development, Chicago, IL *(2001 – 2002)*

Responsible for developing, executing and communicating global marketing & business development strategies for the Abbott Cardiovascular Franchise in the fields of hypertension (Tarka, Gopten, Isoptin), thrombosis, (Clivarine) and arrhythmia (Rytmonorm) in international markets toward 50 affiliates, for sales exceeding $350M.

- Led international relaunch of the Knoll Cardiovascular products.

Director, Commercial Operations, Europe Area, Chicago, USA *(2000 – 2001)*

Responsible for all aspects of commercial operations for Abbott's European affiliates, including the development and implementation of corporate objectives, strategies and tactics. In association with the Vice-President of Europe, had direct P&L responsibility (over $800M) primary focus on Austria, Belgium, Greece, Ireland, Netherlands, Portugal, and Switzerland.

- Developed the neonatal franchise, increasing SYNAGIS® (monoclonal antibody for the prevention of RSV infection in premature babies) sales from $15M (2000) to $30M (2001).
- Following the acquisition of KNOLL / BASF Pharma, contributed to the achievement of planned integration and synergies.

Senior Manager, Anti-Infectives, International Marketing & Business Development, Chicago, IL *(1999 – 2000)*

Developed, executed and communicated global marketing strategies for Abbott's leading antibiotic Clarithromycin (BIAXIN) in international markets toward 50 affiliates, for sales exceeding $700M. Responsible for a multi-million dollar marketing budget.

- Conceived and directed the worldwide relaunch of Clarithromycin (BIAXIN) Once-a-Day. Integrated vastly different markets behind one core marketing, medical and regulatory strategy.
- Led business development and licensing processes with a major European Pharma company in the field of eradication of Helicobacter Pylori.

Director of Marketing France, Paris, France *(1997 – 1999)*

Developed and executed marketing strategies for pharmaceutical products (Anti-infectives, Gastroenterology, Urology) in France; achieved sales of $50M.

- Reversed previous unfavorable sales and market share trend for Clarithromycin (BIAXIN®) into a strong and durable positive trend, with #1 progression in Anti-infective market, and #1 position in Macrolide market.

EARLY EXPERIENCE: SMITHKLINE BEECHAM, Paris, France (1996 – 1997); **Director, Market Research & New Product Planning;** ELI LILLY & CO., Paris, France (1993 – 1996) **Product Manager, PROZAC;** EFFICOM SERVICE, Paris, France (1987 – 1991), **Partner.**

EDUCATION

Doctor of Medicine (MD), FACULTE NECKER-ENFANTS MALADES, Paris, France (1991)

Post Graduate Degree, Molecular and Cellular Pharmacology, ECOLE NORMALE SUPERIEURE, Paris, France (1992)

Graduate Degree, Biochemistry, ECOLE NORMALE SUPERIEURE, Paris, France (1987)

Honors: Ranked first in the biology-medicine section entrance exam at Ecole Normale Superieure of Paris.

OTHER

Board of Directors, SAREPTA THERAPEUTICS (since September 2015).

Fluent in English and French; conversant in German; sports (cardio training, skiing), and classical music enthusiast.